HSE wants Pembro for all women with cervical cancer

The HSE wants the state to fund the drug Pembro for more women with cervical cancer.

Professor Michael Barry, who leads the HSE’s Medicines Management Programme, has proposed the introduction of a managed access programme.

Under this proposal, all patients with cervical cancer would be able to access the drug. It typically takes about eight months to see whether individual patients respond to Pembrolizumab, which is called Pembro for short.

Barry has proposed ...